Glypressin (Terlipressin Acetate)

Glypressin is a prescription injectable medication that contains the synthetic vasopressin analog terlipressin acetate. It is supplied as an intravenous solution, though the exact strength is not publicly specified. Glypressin belongs to the vasoconstrictor therapeutic class and acts as a V1‑receptor agonist. It is marketed in the European Union for clinical use in conditions associated with portal hypertension and variceal bleeding treatment as a therapeutic option.

Glypressin is indicated for the management of acute bleeding related to portal hypertension.

- Control of active esophageal variceal hemorrhage in patients with cirrhosis. - Reduction of portal venous pressure during endoscopic or pharmacologic therapy. - Adjunctive treatment for bleeding gastric varices when conventional measures are insufficient. - Temporary stabilization of hemodynamics in patients awaiting definitive portal decompression procedures. - Management of bleeding from ectopic varices associated with portal hypertension. - Supportive therapy in patients with hepatorenal syndrome secondary to severe portal hypertension.

The pharmacologic activity of Glypressin can produce a range of adverse effects, which are typically categorized by frequency and severity.

Common: - Headache or facial flushing. - Nausea, vomiting, or abdominal discomfort. - Transient hypertension or increase in blood pressure. - Peripheral edema or swelling of the extremities.

Serious: - Myocardial ischemia or chest pain. - Severe hypertension leading to hypertensive crisis. - Cardiac arrhythmias, including tachycardia. - Ischemic limb events or digital necrosis.

Before initiating Glypressin therapy, clinicians should evaluate several patient‑specific factors to minimize risk.

- Known hypersensitivity to terlipressin acetate or any component of the formulation. - Pre‑existing cardiovascular disease, such as coronary artery disease or uncontrolled hypertension. - Severe hepatic impairment or advanced cirrhosis with portal hypertension. - Renal dysfunction, especially in patients with hepatorenal syndrome. - Pregnancy and lactation status, as safety data are limited. - Concomitant use of other vasoconstrictive agents that may amplify blood pressure effects.

Glypressin may interact with other medications, altering its vasoconstrictive effect or increasing adverse event risk.

Avoid: - Other vasopressin analogs or potent vasoconstrictors (e.g., norepinephrine, phenylephrine). - Monoamine oxidase inhibitors (MAOIs) that can potentiate hypertensive responses.

Use with caution: - Beta‑blockers, which may mask tachycardia. - Diuretics, due to potential electrolyte disturbances. - Anticoagulants, as changes in portal pressure could affect bleeding risk. - Drugs affecting hepatic metabolism, such as certain antifungals or macrolide antibiotics.